This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Breast cancer anti-estrogen resistance protein 3.
May also be regulated by cellular adhesion to extracellular matrix proteins. .
Human | |
---|---|
Gene Name: | BCAR3 |
Uniprot: | O75815 |
Entrez: | 8412 |
Belongs to: |
---|
No superfamily |
breast cancer estrogen resistance 3; dJ1033H22.2 (breast cancer estrogen resistance 3); KIAA0554; Novel SH2-containing protein 2; NSP2SH2D3Bbreast cancer estrogen resistance protein 3; SH2 domain-containing protein 3B
Mass (kDA):
92.566 kDA
Human | |
---|---|
Location: | 1p22.1 |
Sequence: | 1; NC_000001.11 (93561741..93847219, complement) |
Cytoplasm. Cell junction, focal adhesion. Localization to focal adhesions depends on interaction with PTPRA.
This article will discuss the BCAR3 marker and the cell-based ELISA kit that uses it. Boster scientists can submit their results for various applications and species. The results they submit can be considered for product credits, which are valid for scientists around the world. Listed below are some of the benefits of using a BCAR3 marker in your experiments. Read on to learn more!
An ELISA kit for the Boster BioBCAR3 marker measures the level of BCAR3 in human plasma, serum, or tissue homogenates. The test is easy to use and can monitor the expression profile of BCAR3 in cell culture samples. Using an ELISA kit, researchers can screen the effects of different treatments and activators on BCAR3 levels. This kit can be used in both research and diagnostic applications.
A good ELISA kit should contain high-affinity antibodies, which are necessary to detect the BCAR3 protein. Boster Bio has mastered the art of coating ELISA plates with high-affinity antibodies. It also provides a step-by-step guide to create a standard curve for accurate results. An ELISA kit for the Boster Bio BCAR3 marker should contain high-affinity antibodies to ensure that the results are accurate.
Boster Bio offers over 1,000 ELISA kits. With over 20 years of experience in the manufacture of antibodies, Boster Bio ELISA kits are sensitive, specific, stable, and rigorously validated. Boster Picokine(tm) ELISA kits are trusted by over 14,000 scientists worldwide and contain high-affinity antibodies that detect native-form proteins. Boster Bio ELISA kits also contain highly sensitive antigen detection.
A good ELISA kit must also be validated for a variety of samples. Some ELISA kits have been validated to detect Boster BCAR3 in serum, plasma, and tissue samples. A good ELISA kit should also be validated for 90% sequence identity, which indicates a high possibility of cross-reactivity. Once you have validated the Boster Bio BCAR3 ELISA kit, you can use it for research purposes.
The ELISA kit for the Boster BioBCAR3 marker includes two panels that include age, gender, and body mass index. The fibrosis markers include SELE and COLEC11.
The expression of BCAR3 is a major marker of prostate cancer and has a diverse function in prostate development. It is known to be expressed in the germ and sertoli cells of the developing testis. Its expression is regulated by its interaction with the adapter protein PTPRA, which is also expressed in breast cancer cells. This research suggests that BCAR3 may act as an adapter protein in the prostate and breast cancer, allowing it to connect activated growth factor receptors to a signaling pathway that regulates cell proliferation. In breast cancer cell lines, BCAR3 overexpression confers anti-estrogen resistance.
The expression of BCAR3 was assessed for a total of 308 samples, including BCAR3-positive and -negative cells. It was found to be highest in the CD1 and CD2 subtypes, and lowest in the PR (proliferation) subtype. These results were analyzed with ANOVA. For further comparison, the BCAR3 gene expression was examined in different ISS stages, serotypes, and ISS stage.
In the study of 66 patients with MM, expression of BCAR3 was found to be significantly different between non-relapse groups and relapsed patients. In the relapse-free group, the expression level of BCAR3 was higher than in the non-relapsed group, indicating that low levels of this marker might indicate a risk of early relapse. However, low expression of this gene may also predict early relapse, a risk factor that should be analyzed further.
The expression of BCAR3 in breast cancer tumors is closely related to the ER protein and has been associated with anti-estrogen resistance in cancer cells. In addition to its anti-estrogen activity, BCAR3 is associated with breast cancer outcomes. Interestingly, R743A BCAR3 lacks the ability to bind p130Cas. In addition, overexpression of BCAR3 promotes cell migration and invasion.
The BCAR3 cell-based ELISA kit is a multifunctional reagent that allows the quantification of the BCAR3 protein, as well as its effect on the expression of different cell lines. Antibodies to BCAR3 capture the protein and HRP-conjugated secondary antibodies detect it. The HRP enzyme is conjugated to the secondary antibody and catalyzes the colorimetric reaction. It contains several methods of normalization to allow for the highest level of accuracy.
Compared with western blotting, ELISA can detect protein phosphorylation and its expression levels. The ELISA procedure is more quantitative and shows its utility in studying modulating kinase activity. The BCAR3 marker ELISA kit uses a microplate-based assay that incorporates a capture antibody. The target protein is bound to the antibody-coated plate. The detection antibody is then added to the phosphorylation site. The intensity of the phosphorylated protein is proportional to the amount of phosphorylated protein present.
The BCAR3 cell-based ELISA kit has several advantages over other methods. It is sensitive and highly specific to the BCAR3 protein. In addition to being specific to the BCAR3 protein, the kit has the added benefit of eliminating the need to prepare a lysate. The 96-well plate is sterile and treated for cell culture, and two enzyme-conjugated secondary antibodies are already included. During the next step, a solution of 100 uL of Poly-L-Lysine is added to the suspension cells.
The present invention also relates to novel b-cell markers, methods of identifying functionally mature b-cells, and agents capable of modulating the maturation of b-cells. The agents can be used to produce unlimited amounts of functionally mature b-cells and administer them to individuals with b-cell deficiency. This invention is highly useful in clinical settings.
This kit has been designed to analyze the expression of a molecule called BCAR3 in human b-cells. This molecule is expressed in insulin-positive cells. The R2 correlation coefficients between the two levels of b-cell transcription are very high. The results of the ELISA kit are highly specific and accurate in determining the B-cell status.
In addition to providing a specific ELISA for the BCAR3 marker, this invention provides a method of distinguishing b-cells from non-b-cells in pancreatic cells. This method involves the collection of a pancreatic cell sample and measurement of the expression of a plurality of genes in the sample. The resulting transcriptome of the pancreatic cells is compared to a reference b-cell transcriptome.
PMID: 9582273 by van Agthoven T., et al. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.
PMID: 10187783 by Lu Y., et al. NSP1 defines a novel family of adaptor proteins linking integrin and tyrosine kinase receptors to the c-Jun N-terminal kinase/stress- activated protein kinase signaling pathway.